Evidence map›Paper›PMID 24047152›Full record

ArticleBMC biotechnology2013

Rapid targeted gene disruption in Bacillus anthracis.

Roland J Saldanha, Adin Pemberton, Patrick Shiflett, Jiri Perutka, Jacob T Whitt, Andrew Ellington, Alan M Lambowitz, Ryan Kramer, Deborah Taylor, Thomas J Lamkin

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. TheMicrobiology spectrum · 2019
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Roland J SaldanhaAir Force Research Laboratory, Air Force Research Laboratory, 711th HPW/RHXBC, Molecular Signatures Section, 2510 Fifth Street, Area B, Bldg 840, Room W220, Wright-Patterson AFB, OH 45433-7913, USA. Thomas.Lamkin@wpafb.af.mil.
Adin Pemberton
Patrick Shiflett
Jiri Perutka
Jacob T Whitt
Andrew Ellington
Alan M Lambowitz
Ryan Kramer
Deborah Taylor
Thomas J Lamkin
The University of Texas at Austin · USUnited States Air Force Research Laboratory · USUES (United States) · USJackson Foundation · US

Funding

RETROPLASMID AND GROUP II INTRON REVERSE TRANSCRIPTASESR01GM037949 · NIGMS · UNIVERSITY OF TEXAS AUSTIN · PI LAMBOWITZ, ALAN M. · 1986 to 2019
$8.6M
NIGMS NIH HHS GM037949
6 · The paper itself

Abstract

backgroundAnthrax is a zoonotic disease recognized to affect herbivores since Biblical times and has the widest range of susceptible host species of any known pathogen. The ease with which the bacterium can be weaponized and its recent deliberate use as an agent of terror, have highlighted the importance of gaining a deeper understanding and effective countermeasures for this important pathogen. High quality sequence data has opened the possibility of systematic dissection of how genes distributed on both the bacterial chromosome and associated plasmids have made it such a successful pathogen. However, low transformation efficiency and relatively few genetic tools for chromosomal manipulation have hampered full interrogation of its genome.

resultsGroup II introns have been developed into an efficient tool for site-specific gene inactivation in several organisms. We have adapted group II intron targeting technology for application in Bacillus anthracis and generated vectors that permit gene inactivation through group II intron insertion. The vectors developed permit screening for the desired insertion through PCR or direct selection of intron insertions using a selection scheme that activates a kanamycin resistance marker upon successful intron insertion.

conclusionsThe design and vector construction described here provides a useful tool for high throughput experimental interrogation of the Bacillus anthracis genome and will benefit efforts to develop improved vaccines and therapeutics.

Indexed as

Genes, BacterialGenetic VectorsBacillus anthracisChromosomes, BacterialCloning, MolecularDNA, BacterialEscherichia coliGene TargetingIntronsMutagenesis, InsertionalNucleic Acid ConformationPlasmidsSelection, GeneticDNA, Bacterial

Identifiers

PMID24047152
PMCPMC3848504
OpenAlexW2156851406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.